NASDAQ · RETAIL-MISCELLANEOUS RETAIL · SMALL CAP
Pomdoctor Limited POM
3 fiscal years on record · CNY · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
¥399.9M
▲ 16.7% vs FY2024
EPS · FY25
¥-21.96
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-32.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
CNY 399.9M
Revenue, FY2025 · full 3-year series below
Revenue
Net income
The company lost 33 cents on every revenue dollar this year.
Per share
CNY -21.96
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-29.7%
Net margin-32.7%
Return on assets-170.3%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
CNY 107.6M
total assets, end of FY2025
Total assetsCNY 107.6M
EquityCNY -454.0M
CashCNY 9.6M
Gross debtCNY 134.8M
Net debtCNY 125.2M
DepositsCNY 9.4M
Net debt stands at -28% of equity.
History
3 fiscal years
Every figure from documents filed with the SEC · CNY
Metric
2025
2024
2023
Revenue ¥B
0.4
0.3
0.3
Operating income ¥B
−0.1
−0.0
−0.0
EBITDA ¥B
−0.1
−0.0
−0.0
Income tax ¥B
0.0
·
·
Net income ¥B
−0.1
−0.0
−0.0
EPS, diluted ¥
−21.96
−22.72
−23.04
Dividend / sh ¥
·
·
·
Payout %
·
·
·
ROE %
·
·
·
Shares out B
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
10 of 10
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed